DNDi is a collaborative, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases. DNDi maintains its commitment to develop treatments for: Leishmaniasis; Sleeping Sickness (human African trypanosomiasis); Chagas disease; Paediatric HIV and Filarial diseases. The Initiative is also undertaking R&D projects for hepatitis C and mycetoma, two very different diseases that share one key challenge: the existing system of biomedical innovation has failed to deliver safe, effective, quality products that are affordable to poor populations. Moreover, DNDi is engaged in strengthening endemic country capacity to advance new treatments. The charity integrates capacity strengthening into its projects through knowledge sharing and technology transfers. The objective is to increase the chances of registration, uptake, and sustainable access of new treatments and, ultimately, to support the transfer of ownership to disease-endemic countries.
DNDi’s R&D regional research platforms form part of a broader, positive trend of research networks to maximize worldwide collaborations. The platform brings together key regional actors (ministries of health, national control programs, regulatory authorities, academia, civil society groups, pharmaceutical companies, clinicians and health professionals) to share different experiences, knowledge, and problem-solving techniques. In addition, DNDi is involved in advocacy for increased public responsibility and a more enabling environment for neglected disease R&D.
The news & stories section has press releases, scientific articles, documents by type of diseases and events as well as videos..
Health information technology and management, Neglected tropical diseases